International deal-making has long been a goal of maximizing value in the biopharma landscape. Navigating cultural norms, understanding reimbursement and regulatory protocols and assessing market opportunity can be daunting for clients who wish to partner in ex-US territories, particularly in Asia. We have found that executing a well-defined deal strategy for Asia enables clients to raise non-dilutive capital, maximize asset value and retain rights in their domestic markets. We are fortunate to have the hands-on deal and operating expertise to offer clients the following:
- Sell-side regional deal processes allow clients to realize value from their asset outside their domestic
- Buy-side sourcing adds to a growth biopharma’s deal flow that is below the radar
- Private financing from Asian investors who are increasingly interested in investing in US/foreign companies
Meet our Managing Director for Asia, Steve Engen. Steve brings over 20 years of executive-level experience, the majority of which has been spent in Japan/Asia. He is fluent in Japanese and is able to gain access to criticial decision-makers in Japanese/Asian biopharmacticeutical companies.
Asian Capabilities Transaction Highlights
CLIENT: TesoRx Pharma LLC
PARTNER: ASKA Pharmaceutical
Advised on expansion of existing collaboration on TSX-011 (oral testosterone) by adding SE Asia territory and expanding scope to CDGP indication, in addition to ASKA equity investment in TesoRx.
CLIENT: Spero Therapeutics
PARTNER: Meiji Seika Pharma Co.,Ltd
Advised on Japan buy-side process leading to exclusive License Agreement for Meiji’s novel oral carbapenem, SPR-994
CLIENT: Veloce BioPharma LLC
Advised on Japan sell-side process leading to the Japan licensing for the company’s dermatology asset, VBP-926, and an equity investment from the partner.